ERBB2 and gastroesophageal junction adenocarcinoma: This is intended for the initial treatment of patients dealing with unresectable, locally advanced, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma, specifically those with CLDN18.2-positive tumors [48].